Innate Pharma SA vs Opus Genetics
Opus Genetics is the larger business, with $14.2m of revenue in fiscal 2025 against $10.2m for Innate Pharma SA (1.4 times as much). Opus Genetics grew faster (29.1% against -53.2%). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -546.1%.
| Latest fiscal year | Innate Pharma SAIPHA, 2025 | Opus GeneticsIRD, 2025 |
|---|---|---|
| Revenue | $10.2m | $14.2m |
| Revenue growth | -53.2% | 29.1% |
| Net income | −$55.6m | −$49.6m |
| Operating margin | -599.8% | -271.9% |
| Net margin | -546.1% | -349.3% |
| Return on equity | — | — |
| Free cash flow | −$59.8m | −$35.3m |
| Cash | $33.0m | $45.1m |
| Total debt | $0 | $1.1m |
| Debt to equity | — | 7.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 27 |
| Market value | $125m | $306m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 23 sales |